EPISODE · Jan 25, 2026 · 23 MIN
The present and future directions of metastatic prostate cancer treatment
from EAU Podcasts · host European Association of Urology
In this episode, UROONCO PCa Associate Editor Assoc. Prof. Pawel Rajwa (PL) interviews medical oncologist Prof. Silke Gillessen Sommer (CH) about the present and future directions of metastatic prostate cancer treatment.They discuss the greatest survival gains in metastatic prostate cancer over the past decade, triplet therapy in mHSPC and patient selection, the role of PSMA-PET imaging and sequencing of systemic therapies in metastatic prostate cancer, biomarker-driven treatment selection, and finally where the future of metastatic prostate cancer treatment is heading.Here are the links to the articles and event which were mentioned in this podcast: EORTC GUCG 2238 De-escalate trialCAPItello-281 phase III studyAPCCC (Advanced Prostate Cancer Consensus Conference)For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Embed this episode
What this episode covers
In this episode, UROONCO PCa Associate Editor Assoc. Prof. Pawel Rajwa (PL) interviews medical oncologist Prof. Silke Gillessen Sommer (CH) about the present and future directions of metastatic prostate cancer treatment. They discuss the greatest survival gains in metastatic prostate cancer over the past decade, triplet therapy in mHSPC and patient selection, the role of PSMA-PET imaging and sequencing of systemic therapies in metastatic prostate cancer, biomarker-driven treatment selection, ...
NOW PLAYING
The present and future directions of metastatic prostate cancer treatment
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.